Stefanie Flückiger-Mangual (left) and Julie Cherrington
Tolremo raises $39M Series A to advance drug designed to dismantle early cancer defenses
Tolremo Therapeutics has completed a $39 million Series A to fund a Phase I trial for its lead candidate in solid tumors. The company is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
